DAVENPORT & Co LLC Acquires 157,216 Shares of Enovis Co. (NYSE:ENOV)

DAVENPORT & Co LLC increased its position in Enovis Co. (NYSE:ENOV - Free Report) by 6.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,782,341 shares of the company's stock after buying an additional 157,216 shares during the quarter. DAVENPORT & Co LLC owned about 4.98% of Enovis worth $121,181,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Pinnacle Bancorp Inc. grew its stake in shares of Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after acquiring an additional 300 shares in the last quarter. Aigen Investment Management LP raised its holdings in shares of Enovis by 5.1% during the third quarter. Aigen Investment Management LP now owns 8,859 shares of the company's stock valued at $381,000 after buying an additional 430 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after buying an additional 437 shares during the last quarter. FMR LLC raised its holdings in Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after purchasing an additional 484 shares in the last quarter. Finally, Heritage Family Offices LLP grew its position in Enovis by 16.6% in the fourth quarter. Heritage Family Offices LLP now owns 5,585 shares of the company's stock worth $245,000 after buying an additional 794 shares during the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a "buy" rating and set a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $65.86.

Enovis Stock Performance

ENOV stock traded up $0.83 during mid-day trading on Wednesday, reaching $46.94. 200,395 shares of the stock traded hands, compared to its average volume of 1,141,968. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average of $46.01 and a two-hundred day moving average of $44.50. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The firm has a market capitalization of $2.67 billion, a PE ratio of -21.43 and a beta of 1.94.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $505.22 million during the quarter, compared to analysts' expectations of $504.44 million. During the same quarter last year, the company earned $0.56 earnings per share. The firm's revenue was up 21.0% on a year-over-year basis. As a group, equities analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.